Guardant Health to showcase new data at ESMO 2022 demonstrating utility of its portfolio of blood tests for advanced-stage cancer patients
Presentations to highlight role of liquid biopsy tests and real-world data to identify biomarkers, predict patient response to therapy, and detect resistance mechanisms in late-stage cancers September 06, 2022 08:05 AM Eastern Daylight Time PALO ALTO, Calif.–(BUSINESS WIRE)–Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, announced today that new…